(S) - () -Ibuprofen

An enantiomer of Ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R) -form; also inhibits activation of NF-κB more effectively than (R) -ibuprofen (IC50=62 and 122 uM, respectively) . (In Vitro) : (S) - (+) -Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S) - (+) -Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis. (S) - (+) -Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S) - (+) -Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation. (S) - (+) -Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM. (In Vivo) : (S) - (+) -Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.